Remepy

Remepy announced $36M in Series A financing on August 12, 2026. Remepy raised a $36 million Series A led by O.G. Venture Partners and M Ventures to expand its Hybrid Drug pipeline and fund Phase III development of Hybridopa for Parkinson’s disease.

Round details

The financing includes backing from O.G. Venture Partners, M Ventures, NFX, Vine Ventures, Qumra Capital, 97212 Ventures, Fresh Fund, PsyMed Ventures. The company did not publish a valuation with the announcement.

• Round: Series A
• Capital announced: $36M
• Total funding reported: $62M

How the company plans to use the capital

Remepy said the funding will accelerate its pharmaceutical co-development partnerships and the expansion of its Hybrid Drug pipeline and platform. It will also fund the global Phase III clinical development of Hybridopa.

Why this matters for GTM teams

M Ventures, the corporate strategic venture arm of Merck KGaA, Darmstadt, Germany, co-led the round. Remepy describes Hybrid Drugs as a class that combines prescription medicines with personalized, AI-driven therapeutic apps.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Remepy Series A announcement.